Jazz Pharmaceuticals (JAZZ) reported adjusted earnings of 5.30pershareinsecond−quarter2024,beatingtheZacksConsensusEstimateof4.68. Earnings rose 18% year over year.Total revenues in the reported quarter rose 7% year over year to 1.02billion.SalesofXywav,EpidiolexandRylazedrovetheupside.ThereportedfigurebeattheZacksConsensusEstimateof1.0 billion.Quarter in DetailNet product sales rose 2% year over year at $964.1 million. The reported figure beat the Zacks Consensus Estimat ...